Michael Mark

4.5k total citations · 3 hit papers
52 papers, 3.1k citations indexed

About

Michael Mark is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Michael Mark has authored 52 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Surgery, 20 papers in Endocrinology, Diabetes and Metabolism and 18 papers in Molecular Biology. Recurrent topics in Michael Mark's work include Diabetes Treatment and Management (20 papers), Pancreatic function and diabetes (17 papers) and Metabolism, Diabetes, and Cancer (10 papers). Michael Mark is often cited by papers focused on Diabetes Treatment and Management (20 papers), Pancreatic function and diabetes (17 papers) and Metabolism, Diabetes, and Cancer (10 papers). Michael Mark collaborates with scholars based in Germany, United States and United Kingdom. Michael Mark's co-authors include Eric Mayoux, Ele Ferrannini, Thomas Klein, Leo Thomas, Rolf Grempler, Frank Himmelsbach, Matthias Eckhardt, Peter Eickelmann, Achim Sauer and Dale E. Sharp and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Diabetes Care.

In The Last Decade

Michael Mark

45 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

2016 741 citations Michael Mark, Eric Mayoux et al. profile →
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

2011 494 citations Rolf Grempler, Leo Thomas et al. Diabetes Obesity and Metabolism profile →
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition

2020 267 citations Issei Tomita, Shinji Kume et al. Cell Metabolism profile →

Peers

Countries citing papers authored by Michael Mark

Since Specialization

Citations

This map shows the geographic impact of Michael Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Mark more than expected).

Fields of papers citing papers by Michael Mark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Mark. The network helps show where Michael Mark may publish in the future.

Co-authorship network of co-authors of Michael Mark

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Mark. A scholar is included among the top collaborators of Michael Mark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Mark. Michael Mark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Five seconds to safety: detecting and managing critical instability before structured handover in non-trauma patients 2026 ·Scandinavian Journal of Trauma Resuscitation and Emergency Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bernhard Kumle, Philipp Kümpers, (unknown), Michael Mark	0
2	Acidosis as a promising early indicator of mortality among point-of-care parameters and vital signs in non-traumatic critically ill patients 2025 ·Scandinavian Journal of Trauma Resuscitation and Emergency Medicine ·(unknown), (unknown), (unknown), (unknown), Peter Kienbaum, Jörg H. W. Distler, (unknown), Michaël Bernhard, Michael Mark	0
3	Die Toxidromsonne als diagnostisches Instrument im Schockraum 2024 ·Notfall + Rettungsmedizin ·(unknown), Michaël Bernhard, (unknown), (unknown), Bernhard Kumle, Michael Mark, (unknown)	0
4	Resuscitation room management of patients with non-traumatic critical illness in the emergency department (OBSERvE-DUS-study) 2023 ·BMC Emergency Medicine ·(unknown), (unknown), Christian Jung, Georg Wolff, (unknown), Philipp Kümpers, Michaël Bernhard, Michael Mark	14
5	„Expositions(E)-Probleme“ des nichttraumatologischen Schockraummanagements 2023 ·Notfall + Rettungsmedizin ·Bernhard Kumle, Michael Mark, Philipp Kümpers, (unknown), Martin Pin, Niels Hammer, Michaël Bernhard	1
6	Exchange-Technik – sicherer Wechsel von Larynxtubus auf Endotrachealtubus 2023 ·Pneumologie ·Michael Mark, (unknown), Michael Bernhard	0
7	Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns 2023 ·World Journal of Clinical Cases ·(unknown), Michael Mark, Micheal Tadros	1
8	Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans 2023 ·Scientific Reports ·Harald Tammen, Martin Kömhoff, Denis Delić, Søren S. Lund, Berthold Hocher, Sandra Frankenreiter, Rüdiger Hess, Maximilian von Eynatten, Michael Mark, Thomas Klein	2
9	SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition breakdown → 2020 ·Cell Metabolism ·Issei Tomita, Shinji Kume, Sho Sugahara, Norihisa Osawa, Kosuke Yamahara, Mako Yasuda‒Yamahara, Naoko Takeda, Masami Chin‒Kanasaki, Tatsuroh Kaneko, Eric Mayoux, Michael Mark, Motoko Yanagita, Hisakazu Ogita, Shin‐ichi Araki, Hiroshi Maegawa	267
10	Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy 2020 ·Scientific Reports ·Denis Delić, (unknown), Richard Urquhart, (unknown), (unknown), (unknown), Oleg Tsuprykov, Ahmed A. Hasan, Bernhard K. Krämer, Patrick Baum, (unknown), Florian Gantner, Michael Mark, Berthold Hocher, Thomas Klein	25
11	Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin 2018 ·Diabetes Research and Clinical Practice ·Gerd Luippold, Michael Mark, Thomas Klein, Kerstin Amann, Christoph Daniel	8
12	Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis 2017 ·British Journal of Pharmacology ·(unknown), Tom Bretschneider, Andre Broermann, (unknown), Birgit Stierstorfer, Christian A. Kuttruff, Michael Mark	16
13	The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Henrik H. Hansen, Jacob Jelsing, (unknown), Gitte Hansen, Niels Vrang, Michael Mark, Thomas Klein, Eric Mayoux	51
14	Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis 2013 ·Medical Molecular Morphology ·Thomas Klein, Masato Fujii, (unknown), Yuichiro Shibazaki, Kyoko Wakamatsu, Michael Mark, Hiroyuki Yoneyama	61
15	Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitus 2012 ·Diabetes Obesity and Metabolism ·Gerd Luippold, Thomas Klein, Michael Mark, Rolf Grempler	65
16	Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity 2012 ·PLoS ONE ·Matthias Kern, Nora Klöting, Heiko G. Niessen, Leo Thomas, Detlef Stiller, Michael Mark, Thomas Klein, Matthias Blüher	94
17	The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice 2012 ·Journal of Endocrinology ·Jacob Jelsing, Niels Vrang, (unknown), Michael Mark, Thomas Klein	42
18	Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats 2011 ·Diabetes Obesity and Metabolism ·Leo Thomas, Rolf Grempler, Matthias Eckhardt, Frank Himmelsbach, Achim Sauer, Thomas Klein, Peter Eickelmann, Michael Mark	42
19	The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis 2009 ·Liver International ·Detlef Schuppan, Mark D. Gorrell, Thomas Klein, Michael Mark, Nezam H. Afdhal	53
20	The expression of human plasma cholesteryl‐ester‐transfer protein in HepG2 cells in induced by sodium butyrate 1993 ·European Journal of Biochemistry ·Bernhard Sperker, Michael Mark, (unknown)	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact